Sessioni Comunicazioni Orali
Pharmacogenetics and personalized medicine - Session II
Mercoledì 28 Ottobre 2015 / 15.45-17.15
| 54 | Risk of thromboembolic events in metastatic colorectal cancer patients with single nucleotide polymorphisms in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR) Falvella FS., Cremolini C., Miceli R., Niger M., Berenato R., Cheli S., Antoniotti C., Nichetti F., Infante G., Caporale M., Martinetti A., Marmorino F., Sottotetti E., Colombo A., Bossi I., Di Bartolomeo M., de Braud F., Loupakis F., Clementi E., Pietrantonio F. |
| 138 | A genome wide microRNA investigation suggests new biomarkers in suicide and lithium targets Squassina A., Niola P., Lopez JP., Congiu D., Cruceanu C., Deiana V., Chillotti C., Severino G., Alda M., Turecki G., Del Zompo M. |
| 355 | Personalization of linezolid dosing regimen at a tertiary-care hospital setting: how much does it impact on drug exposure and therapy costs? Cojutti P G., Pea F., Baraldo M. |
| 225 | The combination of pharmacogenetic and pharmacokinetic analyses to optimise clomipiramine dosing: a case report Antoniazzi S., Cigliobianco M., Cheli S., Cattaneo D., Tatulli A., Altamura CA., Paoli RA., Clementi E., Falvella FS., Bernardi FF. |
| 546 | Pharmacological characterization of a hNav1.4 sodium channel mutation causing paramyotonia congenita Farinato A., Altamura C., Imbrici P., Conte Camerino D., Desaphy JF. |
| 641 | Pharmacogenetic determinants of response to infliximab in pediatric inflammatory bowel disease Stocco G., Cuzzoni E., Favretto D., Naviglio S., De Iudicibus S., Lucafò M., Fabris M., Cifù A., Taddio A., Martelossi S., Ventura A., Decorti G. |